Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.67 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 7/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 7/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.40 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL871524 | 0.97 | ITGB3 (0.64) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| Acetic Acid SCHEMBL4426462 | 0.96 | ITGB3 (0.63) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| Orbofiban SCHEMBL7854981 | 0.80 | ITGB3 (1.00) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| Orbofiban SCHEMBL7415135 | 0.80 | ITGB3 (1.00) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| Orbofiban SCHEMBL7417473 | 0.78 | ITGB3 (0.95) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| Orbofiban SCHEMBL871101 | 0.77 | ITGB3 (0.93) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| Orbofiban SCHEMBL7411884 | 0.75 | ITGB3 (0.88) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| SCHEMBL7444902 | 0.73 | ITGB3 (0.86) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| SCHEMBL7418895 | 0.72 | ITGB3 (0.71) | ITGB3ITGA2BPRSS1PRSS2PRSS3 | |
| SCHEMBL7448694 | 0.72 | ITGB3 (0.83) | ITGB3ITGA2BPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20250110111-A1 | DISPOSABLE SYSTEM FOR ANALYSIS OF HEMOSTATIC FUNCTION | HEMOSONICS, LLC | 2025-04-03 | — | — | US | claimed |
| EP-4481381-A2 | DISPOSABLE SYSTEM FOR ANALYSIS OF HEMOSTATIC FUNCTION | Hemosonics, LLC (US) | 2024-12-25 | — | — | EP | claimed |
| EP-4439040-A2 | HEPARIN-BASED BLOOD SAMPLER WITHOUT PLATELET ACTIVATION | Radiometer Medical ApS (DK) | 2024-10-02 | — | — | EP | claimed |
| EP-3154343-B1 | RODENT BAIT CONTAINING TWO OR MORE ANTICOAGULATING COMPOUNDS | GULBA DIETRICH (DE) | 2023-10-25 | — | — | EP | claimed |
| US-20230227909-A1 | METHODS OF DETERMINING THE ETIOLOGY OF ACUTE ISCHEMIC STROKES | INSERM INSTITUT NATIONAL DE A SANTE ET DE LA RECH MEDICALE (FR) | 2023-07-20 | — | — | US | claimed |
| US-20230190499-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-22 | — | — | US | claimed |
| EP-4158656-A1 | METHODS OF DETERMINING THE ETIOLOGY OF ACUTE ISCHEMIC STROKES | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2023-04-05 | — | — | EP | claimed |
| US-20230058634-A1 | PREVENTION OF PLATELET ACTIVATION AND CELL DIFFERENTIATION DURING THE PROCESSING OF BLOOD AND BLOOD-RELATED COMPOSITIONS | ZEON CORPORATION (JP) | 2023-02-23 | — | — | US | claimed |
| EP-4093853-A1 | PREVENTION OF PLATELET ACTIVATION AND CELL DIFFERENTIATION DURING THE PROCESSING OF BLOOD AND BLOOD-RELATED COMPOSITIONS | GPB Scientific, Inc. (US) | 2022-11-30 | — | — | EP | claimed |
| JP-2001524534-A | — | — | 2001-12-04 | — | — | JP | claimed |
| US-20010036932-A1 | Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof | SMITHFIELD BIOSCIENCE, INC. | 2001-11-01 | — | — | US | claimed |
| US-20010036913-A1 | Combination therapy for reducing the risks associated with cardiovascular disease | GOULD ROBERT J (US) | 2001-11-01 | — | — | US | claimed |
| US-6251852-B1 | SUCH AS ACUTE CORONARY ISCHEMIC SYNDROME AND Q-WAVE MYOCARDIAL INFARCTION, BY ADMINISTERING A 3-HYDROXY-3-METHYLGLUTARYL COENZYME A (HMG-COA) REDUCTASE INHIBITOR IN COMBINATION WITH A PLATELET AGGREGATION INHIBITOR | MERCK & CO., INC. | 2001-06-26 | — | — | US | claimed |
| US-6235706-B1 | Combination therapy for reducing the risks associated with cardiovascular disease | MERCK & CO., INC. | 2001-05-22 | — | — | US | claimed |
| EP-1035868-A1 | USE OF A FIBRINOGEN RECEPTOR-ANTAGONIST FOR PREVENTING DISSEMINATED INTRAVASCULAR COAGULATION | Wiemann, Gundula (DE) | 2000-09-20 | — | — | EP | claimed |
| WO-2000053168-A2 | SYNERGY BETWEEN LOW MOLECULAR WEIGHT HEPARIN AND PLATELET AGGREGATION INHIBITORS, FOR PREVENTING AND TREATING THROMBOEMBOLIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-09-14 | — | — | WO | claimed |
| EP-0946178-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | Merck & Co., Inc. (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1999027962-A1 | USE OF A FIBRINOGEN RECEPTOR-ANTAGONIST FOR PREVENTING DISSEMINATED INTRAVASCULAR COAGULATION | WIEMANN GUNDULA (DE) | 1999-06-10 | — | — | WO | claimed |
| WO-1998011896-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | MERCK & CO., INC. (US) | 1998-03-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036913-A1 | Combination therapy for reducing the risks associated with cardiovascular disease | HMGCR, PCSK9, APOB | ITGB3 699/4885ITGA2B 740/4885PRSS1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.